Company Description
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions.
The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device.
The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
| Country | United States |
| Founded | 2022 |
| IPO Date | Jan 20, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Quang Pham |
Contact Details
Address: 822 A1A North, Suite 306 Ponte Vedra, Florida 32082 United States | |
| Phone | 904 300 0701 |
| Website | cadrenal.com |
Stock Details
| Ticker Symbol | CVKD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 1937993 |
| ISIN Number | US1276362076 |
| Employer ID | 88-0860746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Quang X. Pham | Chairman and Chief Executive Officer |
| Dr. James J. Ferguson FACC, M.D. | Chief Medical Officer |
| Jeffrey Cole | Chief Operating Officer |
| Dr. Matthew Boxer M.B.A., Ph.D. | Executive Vice President of Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 6, 2026 | D | Notice of Exempt Offering of Securities |
| Apr 1, 2026 | 8-K | Current Report |
| Apr 1, 2026 | 424B5 | Filing |
| Mar 31, 2026 | 10-K | Annual Report |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 12, 2026 | 8-K | Current Report |
| Feb 24, 2026 | 8-K | Current Report |
| Jan 2, 2026 | 424B3 | Prospectus |
| Dec 31, 2025 | EFFECT | Notice of Effectiveness |
| Dec 31, 2025 | D | Notice of Exempt Offering of Securities |